Tirzepatide

Tirzepatide is a dual GIP / GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. By activating both incretin receptors, tirzepatide produces greater weight loss in clinical trials than GLP-1-only agents, up to about 22% of body weight at the highest doses.

The dual mechanism comes with a different pharmacogenetic profile than semaglutide: GLP1R variants matter as they do for any GLP-1 agonist, but GIPR variants also influence response, and they only matter for drugs (like tirzepatide) that hit the GIP receptor.

GLP1R encodes the GLP-1 receptor. A common signal-peptide variant (rs10305420, Pro7Leu) increases receptor signal strength; carriers tend to lose more weight and have more nausea on any GLP-1-active drug, including tirzepatide.

GIPR encodes the GIP receptor. The Glu354Gln variant (rs1800437) reduces GIP receptor function. Carriers of the Gln354 allele have ~1.8-fold higher odds of moderate-to-severe nausea or vomiting on tirzepatide. This effect is specific to tirzepatide and other GIP-active drugs, it does not apply to semaglutide.

The most actionable finding for tirzepatide pharmacogenetics is the GIPR Gln354 effect. If a patient discontinues tirzepatide due to nausea and they carry the GIPR variant, switching to semaglutide is a reasonable next step, semaglutide doesn't activate GIPR and the variant doesn't apply.

For GLP1R, the picture is the same as for semaglutide: Leu7 carriers tend to lose somewhat more weight but also experience more GI side effects. This effect operates on the GLP-1 arm of tirzepatide alongside any GIPR effect.

GLP1R Typical Response + GIPR Normal Function

• Effect: Average weight loss and average GI side-effect risk.
• Recommendation: Standard 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg titration.

GIPR Decreased / Poor Function (Gln354 carrier)

• Effect: Higher risk of moderate-to-severe nausea or vomiting on tirzepatide.
• Recommendation: Consider a slower dose-escalation schedule. If GI side effects become intolerable, semaglutide is unaffected by this variant and may be a better tolerated alternative.

GLP1R Enhanced Response

• Effect: Slightly greater weight loss and modestly higher nausea/vomiting risk from the GLP-1 arm.
• Recommendation: Standard titration with a low threshold to slow if side effects emerge.

Indeterminate / Not Available

• Recommendation: Standard titration; monitor response.

GIPR Guidance

For patients with GIPR Decreased or Poor Function who can't tolerate tirzepatide despite slowed titration, semaglutide (Ozempic / Wegovy) is a GLP-1-only alternative that is unaffected by the GIPR variant. Retatrutide, currently investigational, also activates GIPR and is expected to share the same Gln354 sensitivity.

• Nature, 2025 — GLP1R / GIPR variants and incretin response
• FDA — Tirzepatide / Zepbound approval

Learn more about how genetics may affect your response to Tirzepatide and related medications:

• Retatrutide Pharmacogenetics: Triple Agonist Genetics (Investigational)
• Why Isn't Ozempic or Wegovy Working for Me? The GLP1R Connection
• Tirzepatide (Mounjaro, Zepbound) Not Working: GLP1R and GIPR Genetics